Studies back drugs for gout and colitis

12/8/2005 | Wall Street Journal, The

The studies cited TAP Pharmaceutical Products' febuxostat, which is awaiting U.S. approval, as showing promise against gout while Centocor's infliximab was shown to sharply reduce bloody diarrhea, abdominal cramps and other symptoms associated with ulcerative colitis. Infliximab is sold as Remicade for arthritis and Crohn's disease.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI